Xarelto Monotherapy Noninferior To Combination Therapy For Cv | Latest News RSS feed

Xarelto Monotherapy Noninferior To Combination Therapy For Cv - Latest News


Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes

All groups had similar baseline characteristics including an average A1c of 8% and were either drug naive or on metformin monotherapy. Subjects received 16 weeks of active therapy and were then ... read more

Add your link right here

Add your story here to improve SEO, search ranking and drive traffic to your website. Your link will be permanently featured right on this page. To add a link on diferent page, just visit the page you want to show your link and click "Add your link right here". You can use search form below to find the page. read more

ACC announces lineup for late-breaking trials

The American College of Cardiology has announced the lineup of late-breaking clinical trials scheduled for presentation at the 2020 Scientific Session. The ACC Scientific Session will be held ... read more

Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with

Before it's here, it's on the Bloomberg Terminal. read more

Looking for another news?


Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes

The combination of ... sitagliptin as add-on therapy to metformin and is also set to conclude in 2014. Additional upcoming trials will include a randomized, parallel CV outcome trial of ITCA650 ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us